This feasibility trial studies the use of gallium-68 (68Ga)-FAPI as the imaging agent for
positron emission tomography (PET)/computed tomography (CT), collectively PET/CT, in patients
with various cancers. PET uses a radioactive substance called 68Ga-FAPI, which attaches to
cancer activated fibroblasts. The PET scanner takes pictures that capture where the
radioactive drug is "lighting up" and attaching to tumor cells, which may help doctors
recognize differences between tumor and healthy tissue. CT uses X-rays to make a picture of
areas inside the body. Using 68Ga-FAPI in diagnostic procedures, such as PET/CT, may allow
doctors to identify smaller tumors than standard imaging.